BioInvent International (OMXS:BINV) announced today the first results from the BI-505 phase I study in patients with multiple myeloma. The study has reached a final stage and the preliminary analysis shows that BI-505 has an advantageous safety profile. In cohorts where extended therapy was available, 24 % of the patients had stable disease for at least two months, indicating effect of BI-505. The final conclusions of the study will be available at a later time-point. The optimal dose has been defined according to the study protocol and will be used in the next clinical trial which is approved by the health authorities.
Cristina Glad, CEO of BioInvent, commented: "We are delighted that this phase I trial has shown that BI-505 has an advantageous safety profile and that stable disease is observed in a significant number of patients. Although this is still early stage data, the results are encouraging and add to our excitement about the potential of this therapy to significantly improve the treatment of patients with multiple myeloma. We look forward to progress with BI-505 into further development."
"These results are of significant clinical interest. I am very encouraged by the safety profile of BI-505 and by the fact that in this heavily pretreated population, we were noticing patients with stable disease for quite some time." said the Coordinating Investigator of the BI-505 study, Guido Tricot, M.D., at the University of Iowa in Iowa City. "We look forward to further clinical trials with this antibody to determine its full potential, with the goal of ultimately improving outcomes for myeloma patients."
BI-505 is a human antibody selected from the n-CoDeR®-library and fully owned by BioInvent. It is directed against the ICAM-1 adhesion protein, which is highly expressed on multiple myeloma cells. BI-505 has demonstrated significant anti-tumor activity in several relevant models of multiple myeloma.